Detalhe da pesquisa
1.
Current Status and Future Perspectives on MRNA Drug Manufacturing.
Mol Pharm
; 19(4): 1047-1058, 2022 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35238565
2.
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Clin Cancer Res
; 14(4): 1208-17, 2008 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18281556
3.
Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection.
Methods Mol Biol
; 1792: 193-203, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29797261
4.
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Mol Cancer Ther
; 5(7): 1854-63, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16891472
5.
Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems.
Curr Gene Ther
; 6(4): 505-33, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16918337
6.
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Clin Cancer Res
; 10(19): 6638-49, 2004 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15475454
7.
The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.
Curr Drug Deliv
; 2(4): 341-51, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16305437
8.
Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications.
Methods Mol Biol
; 1141: 109-20, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24567134
9.
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Breast Cancer Res Treat
; 106(3): 319-31, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17347776